Related Experiment Video
Updated: Feb 16, 2026

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
Published on: January 9, 2018
Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor
Alexander D Barrow1, Melissa A Edeling1, Vladimir Trifonov2
1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Abstract:
Many tumors produce platelet-derived growth factor (PDGF)-DD, which promotes cellular proliferation, epithelial-mesenchymal transition, stromal reaction, and angiogenesis through autocrine and paracrine PDGFRβ signaling. By screening a secretome library, we found that the human immunoreceptor NKp44, encoded by NCR2 and expressed on natural killer (NK) cells and innate lymphoid cells, recognizes PDGF-DD. PDGF-DD engagement of NKp44 triggered NK cell secretion of interferon gamma (IFN)-γ and tumor necrosis factor alpha (TNF-α) that induced tumor cell growth arrest. A distinctive transcriptional signature of PDGF-DD-induced cytokines and the downregulation of tumor cell-cycle genes correlated with NCR2 expression and greater survival in glioblastoma. NKp44 expression in mouse NK cells controlled the dissemination of tumors expressing PDGF-DD more effectively than control mice, an effect enhanced by blockade of the inhibitory receptor CD96 or CpG-oligonucleotide treatment. Thus, while cancer cell production of PDGF-DD supports tumor growth and stromal reaction, it concomitantly activates innate immune responses to tumor expansion.
Insights
Platelet-derived growth factor (PDGF)-DD promotes tumor growth, but its recognition by NKp44 on natural killer (NK) cells triggers anti-tumor immune responses. This interaction leads to cytokine release and tumor cell growth arrest, offering a potential therapeutic target.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumors often produce platelet-derived growth factor (PDGF)-DD, which drives cancer progression via PDGFRβ signaling.
- This signaling pathway promotes cellular proliferation, epithelial-mesenchymal transition, stromal reaction, and angiogenesis.
Purpose of the Study:
- To investigate the interaction between PDGF-DD and immune cells.
- To determine the functional consequences of this interaction on anti-tumor immunity.
Main Methods:
- Screening of a secretome library to identify PDGF-DD binding partners.
- Analysis of NK cell activation and cytokine production upon PDGF-DD engagement.
- Correlation of gene expression signatures with NKp44 (NCR2) expression and patient survival in glioblastoma.
- In vivo studies using mouse models to assess tumor control.
Main Results:
- The immunoreceptor NKp44, expressed on NK cells, was identified as a receptor for PDGF-DD.
- Engagement of NKp44 by PDGF-DD stimulated NK cells to secrete interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α).
- These secreted cytokines induced tumor cell growth arrest.
- Higher NCR2 expression correlated with a specific transcriptional signature and improved survival in glioblastoma patients.
- NKp44-expressing NK cells demonstrated enhanced control over PDGF-DD-expressing tumors in mice, further improved by CD96 blockade or CpG-oligonucleotide treatment.
Conclusions:
- Tumor-derived PDGF-DD, while promoting tumor growth, also activates innate immune responses through NKp44.
- NKp44-mediated signaling in NK cells triggers anti-tumor cytokine release and growth arrest.
- This pathway represents a potential therapeutic strategy by harnessing innate immunity against PDGF-DD-expressing tumors.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Methods for Controlling Microbial Growth
Population Growth
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity

